Lenalidomide (CC-5013)
Catalog No. A10522
Lenalidomide (CC-5013)是Thalidomide的衍生物。在体外,Lenalidomide具有三种主要活性:直接抗肿瘤作用、抑制肿瘤细胞的微环境支持和免疫调节作用。它通过抑制骨髓基质细胞支持、抗血管生成和抗破骨细胞生成作用以及免疫调节活性直接和间接诱导肿瘤细胞凋亡。
- Daniel A. Rauch, .et al. Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma, Retrovirology, 2020, 17: 27 PMID: 32859220
- A Hayano, .et al. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells, Int J Clin Oncol, 2019, 1-10 PMID: 30993483
- Kumar R, .et al. Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules, Mol Biol Rep, 2018, Oct 11 PMID: 30311125
- Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
Catalog Num | A10522 |
---|---|
M. Wt | 259.3 |
Formula | C13H13N3O3 |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 191732-72-6 |
Synonyms | CC-5013, Revlimid |
SMILES | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N |
Lenalidomide (CC-5013)是Thalidomide的衍生物。在体外,Lenalidomide具有三种主要活性:直接抗肿瘤作用、抑制肿瘤细胞的微环境支持和免疫调节作用。它通过抑制骨髓基质细胞支持、抗血管生成和抗破骨细胞生成作用以及免疫调节活性直接和间接诱导肿瘤细胞凋亡。
In vitro (25°C) | DMSO | 46 mg/mL (177.43 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 5% DMSO+40%PEG 300+5%Tween80+ddH2O | 9 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 38.57 mL | 192.83 mL | 385.65 mL |
0.5 mM | 7.71 mL | 38.57 mL | 77.13 mL |
1 mM | 3.86 mL | 19.28 mL | 38.57 mL |
5 mM | 0.77 mL | 3.86 mL | 7.71 mL |
*The above data is based on the productmolecular weight 259.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.